Dyadic regains compliance with Nasdaq listing rules 5550(a)(2) and 5550(b)

The biotechnology company said its common stock will remain listed on The Nasdaq Capital Market, resolving a continued listing matter highlighted in its latest disclosures.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.